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Antibodies that neutralize diverse strains of HIV-1 develop in 20% of HIV-1-infected individuals, and isola-
tion and structural characterization of these antibodies are revealing how they recognize the envelope glyco-
protein spike. Broadly reactive neutralizing antibodies utilize just a few sites of spike vulnerability and
converge on select modes of recognition. These antibodies have unusual features: uncommonly long
complementarity-determining loops, extensive somatic mutation, or both. Recent advances in next-
generation sequencing of antibody-gene transcripts are providing genetic records of the development of
neutralizing antibodies. These records inform an understanding of the naive B cell repertoire, of somatic
mutation, and of the resulting antibody features that are critical to effective HIV-1 neutralization; based on
these, we propose an ontogeny and structure-based system of antibody classification. The human immune
system is capable of developing antibodies that broadly neutralize HIV-1—and an increasingly detailed view
is accumulating for how effective immunity against HIV-1 can be generated.Introduction
Infection by HIV-1 elicits a robust antibody response to both the
surface unit (gp120) and the transmembrane unit (gp41) of the
envelope glycoprotein (Env) as well as to conformationally
dependent epitopes formed by the trimeric Env spike. However,
these Env-directed responses consist predominantly of non-
neutralizing or strain-specific antibodies (reviewed in Pantophlet
and Burton, 2006; Mascola and Montefiori, 2010). The nature of
this humoral immune response is partially explained by the
structural definition of the HIV-1 Env spike (Figure 1), which
reveals numerous mechanisms of humoral evasion, including
sequence-variable loops, extensive glycosylation, and confor-
mational masking of vulnerable epitopes (Kwong et al., 2002;
Starcich et al., 1986; Wyatt et al., 1998; reviewed in Burton
et al., 2005; Kong and Sattentau, 2012; Pantophlet and Burton,
2006; Verkoczy et al., 2011; Wyatt and Sodroski, 1998). These
work in concert to inhibit the induction of neutralizing antibodies
to conserved Env regions and to impede the recognition of
the viral spike by otherwise potentially protective antibodies.
Augmented by the overall genetic variability of the viral Env,
these mechanisms also provide avenues for viral escape from
the neutralizing antibody response. Indeed, longitudinal studies
of HIV-1 infection have shown viral evolution to outstrip the adap-
tive speed of the antibody-mediated immune response (Albert
et al., 1990; Gray et al., 2007; Pilgrim et al., 1997; Richman
et al., 2003; Rong et al., 2009; Sagar et al., 2006;Wei et al., 2003).
This rather bleak view of the humoral immune response to
HIV-1 dominated the first 20 or so years of HIV-1 research,
punctuated by the isolation and characterization of a few—less
than ideal—cross-reactive neutralizing monoclonal antibodies
(mAbs) such as b12, 2F5, 4E10, and 2G12 (Burton et al., 1994;
Muster et al., 1994; Stiegler et al., 2001; Trkola et al., 1996) as
well as by occasional reports of broadly neutralizing sera elicited
in select HIV-1-infected donors (Binley et al., 2004; Mascola
et al., 1994; Pilgrim et al., 1997). The development of panels of412 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.diverse HIV-1 isolates and highly reproducible neutralization
assays—capable of accurately quantifying the breadth and
potency of HIV-1 neutralization from sera and mAbs (Binley
et al., 2004; Blish et al., 2007; Li et al., 2005; Mascola et al.,
2005; Seaman et al., 2010; Simek et al., 2009)—allowed panels
of sera to be evaluated for their ability to neutralize HIV-1. Start-
ing in2004, several groups of investigators began to report the
identification of sera that could neutralize genetically diverse
strains of HIV-1 (Binley et al., 2004, 2008; Li et al., 2007; Pianta-
dosi et al., 2009; Simek et al., 2009; Wu et al., 2006), with some
sera neutralizing the majority of HIV-1 isolates tested (Binley
et al., 2008; Doria-Rose et al., 2010; Li et al., 2007; Simek
et al., 2009; Tomaras et al., 2011). Longitudinal studies demon-
strated that cross-reactive neutralizing antibodies generally
arose after 2 to 4 years of HIV-1 infection (Gray et al., 2011;Mikell
et al., 2011; Moore et al., 2011), and analyses of such sera pro-
vided initial insights into the viral epitopes targeted by neutrali-
zation antibodies. A number of techniques, including affinity
purification of serum antibodies and neutralization assays with
epitope-specific mutant Env pseudoviruses, were used to
demonstrate that broadly reactive neutralizing sera contained
antibodies to specific regions of the viral Env, including the
CD4-binding site of gp120, glycan-containing regions on the
surface of gp120, and the membrane-proximal external region
of gp41 (MPER) (Binley et al., 2008; Gray et al., 2009a; Li et al.,
2007, 2009; Tomaras et al., 2011; Walker et al., 2010). Together,
these studies provided proof of concept that the immune system
can generate potent neutralizing antibodies against vulnerable
regions of the HIV-1 Env.
Difficulty with defining the specific antibodies responsible for
the observed serum neutralization delayed further insight into
the manner by which the humoral immune system effectively
neutralizes HIV-1. In the absence of neutralizing mAbs that
recapitulate serum neutralization, it was unclear whether serum
neutralization results from polyclonal mixtures of antibodies
Figure 1. HIV-1 Spike and Its Recognition by Neutralizing Antibodies
The20 A˚ cryoelectron tomogram of the HIV-1 BaL isolate viral spike (Liu et al., 2008) is shown in gray, fittedwith three copies of the HIV-1 gp120 core in the CD4-
bound conformation (Pancera et al., 2010a), with modeled glycans and with modeled sites of Env vulnerability colored red (CD4-binding site), green (glycan N160
in V1/V2), blue (glycan N332 at the base of V3), and cyan (MPER of gp41). Effective mAbs are shown that recognize each site (see main text for fuller descriptions
and references). Movie S1 available online shows the viral spike and recognizing antibodies.
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from a more limited subset of antibodies targeting conserved
neutralization epitopes (Binley et al., 2008; Gray et al., 2007;
Li et al., 2007, 2009; Rong et al., 2009; Sather et al., 2009; Scheid
et al., 2009; Stamatatos et al., 2009; Tomaras et al., 2011;Walker
et al., 2010).
Do individual antibodies exist that are capable of neutralizing
diverse strains of HIV-1? The successful identification of the
potent and broadly reactive mAbs PG9 and PG16 in 2009
provided a resounding ‘‘yes’’ to this question. These antibodies
were directed against the variable loop regions 1 and 2 (V1V2)
of the HIV-1 gp120 envelope glycoprotein and were able to
neutralize 70%–80% of viruses tested, often at concentrations
less than 1 mg/ml (Walker et al., 2009). Over the ensuing years,
dozens of additional broadly reactive neutralizing mAbs have
been identified, and sequences for thousands more identified
(Corti et al., 2010; Scheid et al., 2011; Walker et al., 2011; Wu
et al., 2010, 2011b; Zhou et al., 2010). These HIV-1-neutralizing
antibodies arise late in the course of HIV-1 infection and do not
appear to provide substantial clinical benefit to the infected indi-
viduals in whom they occur; however, when present prior to viral
exposure, neutralizing antibodies are able to prevent HIV-1
infection in nonhuman primate models of infection (reviewed inPantophlet and Burton, 2006; Mascola and Montefiori, 2010).
Thus, the generation of neutralizing antibodies in humans by
active or passive immunization may protect against HIV-1
infection. Here we review the identification of broadly neutral-
izing antibodies, the epitopes on the HIV-1 spike that they
target, the molecular tricks they use to achieve their remarkable
breadth, and the B cell ontogenies of their generation and
maturation.
Identification of Human Antibodies Capable of Broadly
Neutralizing HIV-1
In the early 1990s, four human antibodies were identified that
neutralize diverse primary strains of HIV-1 (reviewed in Burton
et al., 2005; Pantophlet and Burton, 2006). One of these, mAb
b12, was isolated from a phage-display library by Barbas, Bur-
ton, and colleagues (Burton et al., 1994), and three others
(2G12, 2F5, and 4E10) were isolated by Trokla, Katinger, and
colleagues (Muster et al., 1994; Stiegler et al., 2001; Trkola
et al., 1996). Although they provided glimpses of the potential
of the human immune system to effectively neutralize HIV-1,
each of these four mAbs was less than ideal. The gp41 mAbs
2F5 and 4E10 demonstrated autoreactive properties (Alam
et al., 2007; Haynes et al., 2005), mAb 2G12 bound to glycansImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 413
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involving heavy-chain swapping of domains (Calarese et al.,
2003), and mAb b12 recognized the CD4-binding site of gp120
via a heavy-chain-only interaction (Zhou et al., 2007). In addition,
mAbs b12, 2G12, and 2F5 displayed less than 50% neutraliza-
tion breadth (Binley et al., 2004; Walker et al., 2009; Wu et al.,
2010) and mAb 4E10 displayed modest potency (Binley et al.,
2004; Zwick et al., 2001).
Although a number of groups expended substantial effort
to identify additional broadly neutralizing human antibodies,
several factors complicated the discovery of such mAbs. These
included the small fraction of B cells that secrete neutralizing
antibodies (<1% of HIV-1-specific B cells), the inefficiency of
traditional EBV transformation methods in creating B cell lines,
the inability to identify and isolate B cells making neutralizing
antibodies, and the lack of high-throughput methods to culture
and screen large numbers of B cells for antibody secretion.
Several methodological advances, however, created a frame-
work for the eventual isolation of numerous neutralizing HIV-1
mAbs. Wardermann, Nussenzweig, and colleagues described
the PCR amplification of heavy- and light-chain antibody regions
from single B cells, which allowed recovery and expression of
antigen-specific mAbs (Tiller et al., 2008; Wardemann et al.,
2003). Poignard and Burton, working with colleagues at Thera-
clone, used a high-throughput microculture method to stimulate
small numbers of B cells (two to six per well) to secrete IgG suit-
able for direct neutralization screening. Antibodies from positive
wells could then be recovered by PCR amplification of heavy and
light chains as noted above, and this led to the identification of
the potent neutralizing mAbs PG9 and PG16. Notably, these
two mAbs bound poorly to recombinant gp120 and thus would
not have been identified without the direct assessment of B
cell supernatants for HIV-1 neutralization (Walker et al., 2009).
The initial isolation of the broadly reactive mAbs PG9 and
PG16 was rapidly followed by additional successes. In early
2010, Weiss, Lanzavecchia, and colleagues used improved
EBV immortalization and culture methodologies to identify
memory B cells making HIV-1-neutralizing mAbs (Corti et al.,
2010). Among the 58 HIV-1-specific mAbs identified, the most
broadly reactive was mAb HJ16, which was directed to the
CD4-binding site of gp120 and could neutralize about 40% of
HIV-1 strains. Also in 2010, Mascola, Nabel, and colleagues
reported the use of an engineered protein probe to identify and
sort epitope-specific B cells (Wu et al., 2010). Starting with the
atomic-level structure of core gp120 (Kwong et al., 1998) and
Rosetta computational tools (Kuhlman et al., 2003), they de-
signed the glycoprotein probe to be stabilized in the CD4-bound
conformation (Zhou et al., 2007) and to have all surfaces altered,
except for the outer domain-contact site for the CD4 receptor
(Wu et al., 2010). This structure-based probe, termed resurfaced
stabilized core 3 (RSC3), was used to fish out select memory B
cells (1 per 1,000 memory B cells) that bound tightly to the
probe and not to a control probe with a mutation in the CD4-
binding site. Single-cell PCR amplification of heavy- and light-
chain sequences led to the recovery of two distinct broadly
neutralizing mAbs, VRC01 (90% breadth) and VRC03 (50%
breadth).
Early 2011 brought additional successes. Bonsignori, Haynes,
and colleagues used aB cell culture and neutralization-screening414 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.approach to isolate four clonally related V1V2-directed mAbs
(CH01–04) that could neutralize up to 50% of HIV-1 strains (Bon-
signori et al., 2011). Burton, Poignard, and colleagues again used
direct neutralization screening of B cell supernatants, but this
time choosing to analyze the four most potent sera from a cohort
(Protocol G) of 1,800 HIV-1-infected donors (Simek et al., 2009).
From each donor, a set of clonally related glycan-dependent
neutralizing antibodies was recovered (PGT121–123, PGT125–
131, PGT135–137, and PGT141–145) (Walker et al., 2011).
Scheid, Nussenzweig, and colleagues reported the development
of new primers that more efficiently amplified highly somatically
matured gene products and used gp140 (Scheid et al., 2009) and
a modified gp120 core (Dey et al., 2009; Zhou et al., 2007) as
probes to fish out several hundred unique antibodies from four
HIV-1-infected donors. A number of these antibodies were
both potent and broadly neutralizing (90% breadth), including
NIH45–46, 3BNC117, and 12A12 (Scheid et al., 2011). Kwong,
Mascola, and colleagues used the RSC3-bait strategy on two
additional donors to identify several potent neutralizing mAbs,
including VRC-PG04 and VRC-CH31, each with 80% breadth
(Wu et al., 2011b). In addition to the recovery of mAbs from
antigen-specific B cells, massively parallel next-generation
sequencing of expressed heavy- and light-chain B cell tran-
scripts (the ‘‘antibodyome’’) was carried out on two donors,
and this identified several thousand variants, many with highly
divergent sequences.
Reports of additional broadly neutralizing HIV-1 antibodies
continue to roll in. New antibodies to the CD4-binding site
(VRC13 and VRC16) (X. Wu et al., 2012, Keystone Symposia:
HIV Vaccines, abstract) and to the MPER of gp41 (10E8)
(Huang et al., 2012) have been recently reported. mAb 10E8 is
of particular interest because it recapitulates the extraordinary
breadth of mAb 4E10 but is 5- to 10-fold more potent and lacks
detectable reactivity with self-antigens. Virtually all of these new
antibodies are being identified by the two strategies described
above: direct neutralization screening of B cell supernatants or
probe-based B cell isolation, both of which recover heavy- and
light-chain sequences from individual B cells. Next-generation
sequencing of antibody-gene transcripts—which determines
many thousands of sequences of the antibodyome and then
attempts to identify sequences of functional importance—offers
a different strategy. Starting with the sequence of a known
neutralizing antibody, sequences of clonal relatives and of
related antibody lineages can be identified using parameters
such as sequence homology, germline divergence, phylogenetic
relationships, or additional bioinformatics signatures (Wu et al.,
2011b; Zhu et al., 2012). This is reviewed in more detail below.
It seems likely that the current approaches of genetic recovery
of antibodies from sorted or cultured B cells and next-generation
sequencing of antibodyomes, or combinations of the two, will
continue to yield additional broadly neutralizing antibodies
against HIV-1.
FourHIV-1 Sites of Vulnerability to Neutralizing Antibody
The HIV-1-viral spike has a number of regions common to
diverse isolates where antibodies might bind and effectively
neutralize. These include the sites on gp120 involved in receptor
binding (for the primary receptor CD4 or for the coreceptors,
CCR5 or CXCR4), exposed variable regions such as V1V2 and
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helices and MPER (Starcich et al., 1986; Wyatt and Sodroski,
1998). Whereas these sites are highly accessible on some labo-
ratory-adapted strains of HIV-1 (Mascola et al., 1996; Wrin et al.,
1995), antibody access to neutralization epitopes on primary
virus isolates appears to be limited by the extensive glycosyla-
tion and overall structural configuration of the trimeric viral spike
(Chen et al., 2009; Decker et al., 2005; Kwong et al., 2002; re-
viewed in Burton et al., 2005; Kong and Sattentau, 2012; Panto-
phlet and Burton, 2006).
The epitopes of the most broadly reactive mAbs—those anti-
bodies capable of neutralizing over 80% of HIV-1 isolates—offer
a means to identify sites of broad vulnerability. Overall, only four
such sites have been identified (Figure 1), three on gp120 and
one on gp41. In addition to recognition by at least one effective
antibody, these sites are also targeted by a number of antibodies
with less breadth, but with epitopes that overlap the site of broad
vulnerability.
The CD4-binding site on gp120 is recognized by a number of
broadly neutralizing mAbs. These include VRC01, NIH45–46,
12A12, 3BNC117, VRC-PG04, and VRC-CH31, which neutralize
80%–90% of viruses (Figure 1) (Scheid et al., 2011; Wu et al.,
2010, 2011b; Zhou et al., 2010). Numerous additional anti-
bodies have been isolated that neutralize with somewhat less
potency and breadth, including b12, HJ16, VRC03, 1B2530,
and 8ANC131 among others (Burton et al., 1994; Corti et al.,
2010; Scheid et al., 2009, 2011; Wu et al., 2010). The CD4-
binding site of the HIV-1 Env is functionally conserved (Kwong
et al., 1998; Wyatt and Sodroski, 1998), though the precise
extent of its vulnerability to antibody recognition is still under
investigation (Falkowska et al., 2012; Wu et al., 2009). Several
liganded crystal structures reveal that VRC01 and related
mAbs partially mimic the CD4 interaction with gp120 and focus
recognition on the site of initial gp120 attachment to CD4 (Diskin
et al., 2011; Wu et al., 2011b; Zhou et al., 2010). Recognition of
the CD4 receptor by the HIV-1 Env involves considerable confor-
mational changes in Env (Kwong et al., 1998;Myszka et al., 2000;
Pancera et al., 2010a), and—in the absence of a structure of the
entire viral spike, which has not yet been determined at atomic-
level resolution—the extent that the CD4-binding site is assem-
bled on primary isolates prior to encounter with cell-surface
CD4 is unclear. Interestingly, several of the most potent CD4-
binding site mAbs have been shown to induce a conformational
change similar to that induced by soluble CD4 upon binding to
recombinant gp120. However, unlike sCD4, these mAbs do not
appear to induce this change on the native viral spike (Falkowska
et al., 2012; Scheid et al., 2011; Wu et al., 2010, 2011b). The
outer domain region of gp120 that first contacts CD4 has been
proposed as a ‘‘site of vulnerability’’ by Kwong and colleagues
(Chen et al., 2009; Zhou et al., 2007), and recognition of this
site, which accounts for about 60% of the entire contact of
CD4, correlates well with neutralization breadth (Zhou et al.,
2010). Bjorkman and colleagues, however, found the potency
of mAb NIH45–46 could be enhanced by a Gly54Trp mutation,
which makes contact with the gp120-bridging sheet region in
a manner analogous to a critical phenylalanine of CD4 (Diskin
et al., 2011). In addition, Weiss and colleagues isolated a near
pan-reactive llama antibody named J3 that also appears to
recognize regions outside the outer domain contact of CD4(McCoy et al., 2012). Lastly, CD4 contacts bridging sheet and
other regions of gp120, not just the outer domain, and shows
substantial breadth (Kwong et al., 1998; Wu et al., 2010). Thus,
a precise definition of the boundary of this site of vulnerability
may require an understanding of the ability of antibody to induce
spike-conformational change, not only a definition of Env-
surface contacted.
A V1V2 site forms a second site of spike vulnerability to
neutralizing antibody. Broadly reactive neutralizing V1V2-
directed mAbs include PG9, PG16, PGT145, and those with
somewhat less potency or breadth, CH01–04 and PGT141–
144. Initial identification of a neutralization site involving residue
160 in the V1V2 region of gp120 involved an extraordinarily
potent antibody (mAb 2909), which recognized rare HIV-1
isolates with a lysine at residue 160 (Gorny et al., 2005; Wu
et al., 2011a). The 2909 antibody appeared to be exclusively
quaternary structure-specific, i.e., it only recognized the assem-
bled viral spike, not individual subunits. The more broadly
neutralizing V1V2-directed antibodies also share a preference
for the assembled viral spike, though some of them, such as
PG9, do recognize select gp120s in the monomeric context.
Interestingly, these antibodies display some dependence on
the V3 regions of the assembled viral spike (Walker et al.,
2009), but in the monomeric gp120 context, this dependence
disappears and recognition occurs with specific V1V2 glycans
in addition to V1V2-peptide contacts. Structural determination
of antibody PG9 with a scaffolded V1V2 revealed a site of recog-
nition involving two glycans and a strand (McLellan et al., 2011)
(Figure 1). A Man5 glycan appeared to be required at residue
N160. Analysis of resistant isolates indicates that the recognized
strand (‘‘strand C’’ of V1V2) is a primary determinant of resis-
tance to all broadly neutralizing antibodies that bind V1V2
(Doria-Rose et al., 2012a). Overall, this region appears to
be susceptible to considerable conformational change. V1V2-
deleted viruses are generally functionally competent for entry,
but not for immune evasion, and it thus appears that the conser-
vation of a glycan at residue N160 is related to immune evasion.
A conserved glycan-V3 site on gp120 forms a third site of spike
vulnerability. Antibodies to this conserved glycan cluster, which
is located on the outer domain of gp120 proximal to the V3 region
(Figure 1), include effective neutralizers PGT121 and PGT128, as
well as those with somewhat less potency or breadth, 2G12,
PGT122–123, PGT125–127, PGT129–131, and PGT135–137.
Initial discovery of this glycan site of vulnerability involved infer-
ences from mutational analysis, modeling, and a number of
structures of mAb 2G12 in complex with various N-linked gly-
cans (Calarese et al., 2003; Sanders et al., 2002; Scanlan et al.,
2002). However, the 2G12 mAb has limited potency and breadth
of reactivity and contains an unusual domain-swapped structure
(Calarese et al., 2003). The finding that three of the most potent
neutralizing sera fromProtocol G contained glycan N332-depen-
dent antibodies was unexpected and raised interest in this
region. The structure of mAb PGT128 in complex with an outer
domain region of gp120 showed recognition of two high-
mannose sugars (attached to residues N301 and N332) as well
as a few residues of the V3 (Pejchal et al., 2011). Mutational anal-
ysis as well as heavy- and light-chain complementation indicates
that these glycan-V3-directed antibodies have diverse modes
of recognition, some recognizing a bit of V3 protein as well asImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 415
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PGT128) and others recognizing only glycans (e.g., 2G12, which
appears to recognize themannose branches ofN-linked glycans
at N295, N332, and N395) (Calarese et al., 2003; Doores et al.,
2010; Walker et al., 2011). So although all of the glycan-V3-
directed broadly neutralizing antibodies appear to recognize
glycans N301 or N332, antibodies from different donors appear
to recognize specific features of the surrounding surface in
diverse ways. Thus, mAbs PGT128, PGT135, and 2G12 all
recognize distinct but overlapping epitopes, where the main
overlap is the involvement of glycan at N332. Like the V1V2
site, the conservation of an N-linked glycan at N332 appears to
be related to immune evasion.
The MPER on gp41 forms a fourth site of spike vulnerability to
neutralizing antibody. mAb 4E10 and the recently described
more potent 10E8 are the two most broadly reactive antibodies
to the MPER of gp41. Other neutralizing mAbs with somewhat
less breadth include 2F5, Z13e1, m66, and CAP206-CH12
(Morris et al., 2011; Muster et al., 1994; Zhu et al., 2011; Zwick
et al., 2001). Of all the sites recognized by effective neutralizers,
the MPER is the only one on gp41 (Figure 1). Like the CD4-
binding site, the conservation of the MPER appears to be related
to the role of gp41 in viral entry (Buzon et al., 2010; Weissenhorn
et al., 1997). Five tryptophans and other highly conserved hydro-
phobic residues are contained in the MPER, and substitution of
these with polar or charged residues leads to severe impairment
of viral entry (Salzwedel and Berger, 2000). Structural definition
of antibodies 4E10 or 10E8 with MPER (Cardoso et al., 2005;
Huang et al., 2012) reveals the MPER to fold into an a helix (resi-
dues 672–683) capped on one end by an Asn, Thr, or Ser at
residue 671 and terminated on the other end by the transmem-
brane-spanning region, which is predicted to start at residue
684. The structure of a late fusion intermediate (Buzon et al.,
2010) indicates that the residues recognized by 4E10 and 10E8
reside on the outside of the postfusion coiled coil (Chan et al.,
1997; Weissenhorn et al., 1997). Notably, the 2F5 and Z13e1
antibodies recognize non-a-helical conformations of the MPER
(Ofek et al., 2004; Pejchal et al., 2009), substantially different
from that of the postfusion structure. Overall, the MPER is
thought to undergo significant conformational changes during
entry and may—in prefusion or intermediate conformations—
interact directly with the viral membrane (Kim et al., 2011; Ofek
et al., 2004; Song et al., 2009; Sun et al., 2008).
Convergence in Recognition by Effective mAb
Neutralizers
Recognition of complex antigens by the humoral immune system
is generally accomplished by a diverse multiplicity of recognition
modes and of recognized surfaces. For example, structural
characterization of HIV-1 V3-directed antibodies shows diverse
recognition (Bell et al., 2008; Stanfield et al., 2006). By contrast,
potent antibodies that target the CD4-binding site, isolated from
half a dozen different donors, all utilize the same mode of heavy-
chain mimicry of the CD4 interaction with gp120, and all recog-
nize the same outer domain contact site of CD4 (Diskin et al.,
2011; Wu et al., 2011b; Zhou et al., 2010) (Figure 1). Structures
of antibodies that target the CD4-binding site but display lower
breadth such as antibodies b12, F105, and b13 (approximately
40%, 10%, and 10% breadth, respectively) show different416 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.modes of recognition and contact different regions of the CD4-
binding site (Chen et al., 2009; Zhou et al., 2007). The likely
explanation—that only very few modes of antibody recognition
allow for broad recognition of the CD4-binding site—indicate
that although the human immune system can recognize this
site, it is pushed to extraordinary limits to do so.
Antibodies 4E10 and 10E8, which both show remarkable near
pan-neutralization, converge in their recognition of very similar
gp41 residues (Cardoso et al., 2005; Huang et al., 2012; Ofek
et al., 2004) (Figure 1). Their modes of antibody recognition,
however, differ considerably, as do the genetic origins of their
heavy and light chains. Unlike 4E10 (Haynes et al., 2005), the
10E8 mAb achieves broad recognition without the property of
reactivity with self-antigens. It is currently unclear whether the
different properties of 4E10 and 10E8 relative to lipid binding
are related to a difference in mode of recognition or represent
different degrees of the intrinsic properties that are coupled to
MPER recognition. Nonetheless, the diverse antibody recogni-
tion at the MPER suggests that the human immune system can
follow a number of different pathways to generate near pan-
neutralization at the MPER.
Antibodies PG9 and PGT128, meanwhile, recognize N-linked
glycans on different regions of the HIV-1 Env but converge in
mode of recognition (McLellan et al., 2011; Pejchal et al., 2011)
(Figure 1). All of the V1V2-directed broadly neutralizing anti-
bodies identified to date appear to have extended anionic
heavy-chain third-complementarity-determining regions (CDR
H3s) (McLellan et al., 2011; Pancera et al., 2010b; Pejchal
et al., 2010; Walker et al., 2009, 2011), though differences in
CDR H3 length, tyrosine sulfation, and a general lack of heavy-
and light-chain complementation (Bonsignori et al., 2011;McLel-
lan et al., 2011; Walker et al., 2009, 2011) indicate that there may
be substantial differences in their exact mode of recognition.
Meanwhile, the glycan-V3-directed broadly neutralizing anti-
bodies also show diverse V gene origins, CDR H3s, and differen-
tial response to substitutions of residues around N332 (Pejchal
et al., 2011; Walker et al., 2011), suggesting a diversity of ways
by which the human immune system can recognize N-linked
glycan. Nonetheless, the convergence in mode of recognition
between PG9 and PGT128—both utilizing an extended CDR
H3 to reach a bit of protein surface, while heavy- and light-chain
CDRs each recognize an N-linked glycan—suggests a limited
number of modes of glycan recognition, which are compatible
with very broad reactivity. It will be interesting to see whether
other glycan-dependent effective neutralizers also use this
mode of recognition. Does the highly effective PGT121, for
example, like PG9 and PGT128, also utilize two glycans and
a bit of Env-protein surface to affect its broad recognition? If
so, then a single mechanism of recognition would be employed
by all of the currently identified highly effective glycan-reactive
HIV-1 neutralizers.
Broadly Reactive Neutralizing Antibodies: Unusual
Features
All of the effective neutralizers against HIV-1 characterized to
date have one or more unusual features. Although the humoral
response during the course of HIV-1 infection consists of many
highly somatically matured antibodies (Breden et al., 2011;
Scheid et al., 2009), the CD4-binding site-directed antibodies
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mutation frequencies of 32% and 20% in heavy- and kappa-
chain V genes (VH and VK), respectively (represented by antibody
VRC01 in Figure 2). This contrasts with themutation level of influ-
enza antibodies during a secondary immune response, which
rarely exceeds 10% (Moody et al., 2011; Wrammert et al.,
2008). These maturation changes appear necessary to evolve
from the weak gp120 recognition of unmutated germline ances-
tors to the high-affinity gp120 recognition of the mature neutral-
izing antibodies (Xiao et al., 2009; Zhou et al., 2010). In addition,
the heavy chains of the most broadly reactive CD4-binding site
mAbs originate from a restricted set of VH genes (VH1-2 or
VH1-46) (Scheid et al., 2011; Wu et al., 2010, 2011b), likely due
to the crucial nature of contact sites encoded by these genes
(West et al., 2012; Wu et al., 2011b; Zhou et al., 2010). The
V1V2-directed effective neutralizers show extraordinarily long
CDR H3s of 24–32 residues by Kabat sequence definition of
CDR (Kabat et al., 1991), which appear to be required to pene-
trate the glycan shield at the V1V2 site of vulnerability (McLellan
et al., 2011; Pejchal et al., 2010) (representative PG9 antibody
shown in Figure 2). Their more moderate somatic maturation
frequencies (11%–18% for VH and 9%–16% for VK or VL) and
varied heavy- and light-chain origin genes (Bonsignori et al.,
2011;Walker et al., 2009, 2011) indicate that once an appropriate
CDR H3s is formed, recognition is compatible with a number of
heavy- and light-chain pairs. The glycan-V3-directed effective
neutralizers have CDR H3s of more moderate length (18–24 resi-
dues) but display a moderate to high degree of somatic matura-
tion (15%–23% for VH and 9%–24% for VK or VL), often involving
insertions or deletions (Walker et al., 2011) (represented by the
PGT128 antibody in Figure 2). The higher degree of somatic
maturation may be required to generate the tighter glycan
binding observed with these antibodies relative to the V1V2-
directed ones. Finally, the MPER-directed effective neutralizers
show moderately long CDR H3s (17–22 residues) and moderate
to high degrees of somatic maturation (13%–21% for VH and
6%–14% for VK or VL) (represented in Figure 2 by the 10E8 anti-
body). The extensive CDRH3 recognition provides a rationale for
extensive restrictions on CDR H3s, and somatic maturation in
this case may be needed to enhance CDR H3 recognition,
perhaps through addition of hydrophobic amino acids with
affinity to membrane (Ofek et al., 2010). Elicitation of effective
neutralizers is likely to require an understanding of how the
immune system generates unusual features such as extensive
somatic maturation and extended CDR H3 loops.
Genetic Records and B Cell Ontogenies
In principle, the memory B cell compartment retains a genetic
record of the antibody response, including both its generation
and maturation (Glanville et al., 2009; Lerner et al., 1991; Tian
et al., 2008). This record can be inferred, or even partially recon-
structed, by the isolation of antigen-specific B cells from various
clonal lineages and by studying variants of a common clonal
lineage (Bonsignori et al., 2011; Haynes et al., 2012; Kashyap
et al., 2008; Moody et al., 2011; Scheid et al., 2009; Wrammert
et al., 2008). In the case of the HIV-1 broadly neutralizing anti-
bodies, immense interest has focused on understanding their
unmutated ancestors and maturation history, because each
effective neutralizer provides a potential template for vaccinationstrategies to elicit a similar antibody response (Burton et al.,
2005; Haynes et al., 2012; Kong and Sattentau, 2012; Moir
et al., 2011; Verkoczy et al., 2011). This is viewed as particularly
important for HIV-1, because current vaccine immunogens do
not induce potent and broadly reactive neutralizing antibodies
(reviewed in Mascola and Montefiori, 2010; Pantophlet and Bur-
ton, 2006). Next-generation sequencing of B cell transcripts has
the potential to permit an in-depth analysis of large sets of
related antibody sequences, thus addressing questions about
initial V(D)J recombination, CDR H3 length, and somatic matura-
tion (see for example Briney et al., 2012b; Wu et al., 2011b).
Despite this interest, the technical challenges required to read
the genetic record of B cell development are substantial,
and—although under investigation by a number of groups—pub-
lished B cell ontogenies are in most cases highly incomplete.
Little is currently known about the exact B cell maturation
pathways for most effective HIV-1-neutralizing antibodies. The
two most broadly reactive MPER-directed mAbs, 4E10 and
10E8, have moderately long CDR H3s (18 and 20 residues,
respectively) and a high degree of somatic mutations (13%
and 21% for VH, 6% and 14% for VK/VL, respectively) (Haynes
et al., 2012; Huang et al., 2012; Zwick et al., 2001) (Figure 2). In
terms of clonal variants, 4E10 was isolated as a single clone
(Stiegler et al., 2001; Zwick et al., 2001), and 10E8 was isolated
along with a single closely related relative (Huang et al., 2012), so
we are unable to infer the exact B cell maturation pathway of
these antibodies. Themost effective glycan-V3-directed neutral-
izing antibodies, PGT121 and PGT128, have moderately long
CDR H3s (24 and 19 residues, respectively) and a high degree
of somatic mutations (17% and 19% for VH, 18% and 9% for
VL, respectively) (Walker et al., 2011) (Figure 2). A handful of
mature clonal variants have been isolated, two for PGT121
(PGT122 and PGT123) and five for PGT128 (PGT125–131).
Even within a clonal B cell family, these antibodies show
substantial divergence in somatic mutations and in glycan-
binding specificity. Thus, the lack of early variants from these
two clonal B cell families makes it difficult to infer the unmutated
ancestor (and CDR H3) or the evolutionary pathway of somatic
maturation. The same is true for the most effective V1V2-
directed antibodies, PG9 and PGT145, which showuncommonly
long CDR H3s (28 and 31 residues, respectively) and amoderate
to high degree of somatic mutations (13% and 18% for VH, 6%
and 16% for VL/VK, respectively) (Walker et al., 2009, 2011)
(Figure 2). In terms of clonal variants, again only a limited number
of mature variants have been obtained, one for PG9 (the PG16
antibody) and four for PGT145 (PGT141–144). Heavy- and
light-chain complementation, swapping of CDR H3s, and V
gene reversion of PG9 and PG16 (Pancera et al., 2010b) as
well as next-generation sequencing of naive templates (Briney
et al., 2012a) suggest an initial rare recombination to produce
a long CDR H3, with weak neutralization. The process of B cell
somatic mutation then greatly enhances recognition, increasing
both breadth and potency of neutralization. Though informative,
the currently limited sampling of the B cell lineage hinders insight
into the initial recombination event that appears to be the primary
barrier to generating these antibodies.
Among the most effective CD4-binding site-directed anti-
bodies, however, larger data sets are available by which to infer
B cell lineages. Unlike the V1V2- or glycan-V3-directed mAbs,Immunity 37, September 21, 2012 ª2012 Elsevier Inc. 417
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Figure 2. B Cell Ontogenies of Broadly
Neutralizing Antibodies
Effective neutralizing human antibodies have
unusual features, a result of unusual recombina-
tion, somatic mutation, or both. CD4-binding site
antibodies, represented here by VRC01, are
described in the top row. A number of effective
neutralizers use mimicry of CD4 by their heavy
chain to effect near pan-neutralization. All of these
derive from similar VH genes, VH1-2 or VH1-46,
but otherwise display a variety of CDR H3
lengths and VK or VL partners. Next-generation
sequencing and systems-level bioinformatics
allow specific CDR H3 lineages to be traced to
identify thousands of clonal variants. For VRC01,
only the more highly somatically matured anti-
bodies are capable of neutralizing HIV-1. V1V2-
directed antibodies, represented here by PG9, are
described in the second row. All V1V2-directed
broadly neutralizing antibodies identified to date
display unusually long CDR H3s. These are likely
required to penetrate the glycan shield to reach
conserved features of Env-protein surface. For
PG9, recombination that generates a 28 amino
acid CDR H3 appears to occur as an early event,
with somatic mutation fine tuning glycan recog-
nition. Glycan-V3-directed antibodies, repre-
sented here by PGT128, are described in the third
row. Antibodies directed toward this site are
highly diverse. Some, such as PGT128, have CDR
H3s that are not so unusual but display high
degrees of somatic mutation. MPER-directed
antibodies, represented here by 10E8, are
described in the bottom row. These gp41-
directed neutralizers are quite diverse, with some
such as 2F5, Z13, and 4E10 requiring significant
degrees of b strand interactions, whereas 10E8
interacts entirely through its CDR loops. Despite
this diversity, all show moderately long CDR H3s
and unusual degrees of somatic mutation.
418 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.
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10 to 16 residues). They do nevertheless have unusually high
degrees of somatic mutation (often exceeding 25% in VH and
15% in VK) (Scheid et al., 2011; Wu et al., 2010, 2011b) (Figure 2).
With these antibodies, substantially greater sampling of clonal
variants has occurred. For example, Scheid, Nussenzweig, and
colleagues used probe-based B cell sorting to identify numerous
clonal relatives of the broadly reactive mAbs 3BNC117 and
12A12 (Scheid et al., 2011). To augment the information attained
by isolation of tens or even hundreds of isolated B cells, next-
generation sequencing technologies can generate hundreds of
thousands of sequence reads across the full spectrum of anti-
body-gene families (Boyd et al., 2010; Prabakaran et al., 2012;
Rothberg and Leamon, 2008; Tian et al., 2008; Wu et al.,
2011b). Currently, 454 pyrosequencing is the only high-
throughput technology with the ability to obtain reads of over
400 bases, thus producing sequences containing the full anti-
body V(D)J variable regions (Rothberg and Leamon, 2008). By
using the 454 platform to sequence B cell antibody transcripts,
Kwong, Mascola, and colleagues analyzed the antibody reper-
toire of the donor from whom the CD4-binding site mAb VRC-
PG04 was isolated. Among 120,000 VH1 family sequences,
they identified several thousand sequences that were members
of the VRC-PG04 clonal family. These sequences contained
a remarkable record of the antibody B cell lineage, ranging
from VH sequences with a single somatic mutation to fully mature
sequences with over 100 nucleotide somatic mutations (Wu
et al., 2011b). Importantly, the less mutated sequences allowed
a clear definition of the heavy-chain unmutated ancestor of VRC-
PG04, and this may be valuable in assessing vaccine immuno-
gens (Haynes et al., 2012; Pancera et al., 2010b; Xiao et al.,
2009). The wealth of clonal variants that can be recovered by
current antibody-isolation technologies, coupled with detailed
structural analysis and antibodyomics analysis of B cell lineages
and developmental intermediates, provides substantial new
insights into the B cell ontogeny of effective CD4-binding site-
directed neutralizers, such as VRC01.
As noted above, the heavy chain of VRC01 and other CD4-
binding site antibodies that mimic CD4 derive from the VH1-2
or the closely related VH1-46 gene. Based on SNP analysis
that distinguishes VH1-2 alleles, an estimated 95% of humans
appear to have the required VH1-2 alleles to encode VRC01-
like antibodies (West et al., 2012), though the full IgG locus
sequencing needed to determine the frequency of human IgG
heavy- and light-chain gene alleles is not yet complete. Interest-
ingly, diverse JH genes and CDR H3 sequences appear to be
compatible with the heavy-chain sequences that make up the
set of VH1-2 neutralizing antibodies (Scheid et al., 2011; West
et al., 2012; Wu et al., 2011b; Zhou et al., 2010). For VRC01-
like light chains, diverse VK genes appear to be compatible,
though there is a requirement for a 5 amino acid CDR L3
(Scheid et al., 2011; West et al., 2012; Wu et al., 2011b; Zhou
et al., 2010). Although only 1% of human CDR L3s have only
5 amino acids (West et al., 2012), substantial numbers of re-
combinants are likely produced in the estimated billion new B
cells that adult humans generate each day. A far more serious
barrier to the elicitation of VRC01-like antibodies appears to be
the poor affinity between the unmutated ancestor of VRC01
and typical variants of HIV-1 gp120 (Wu et al., 2011b; Zhouet al., 2010). The extraordinary degree of somatic mutation
required to develop naive B cell recombinants into effective
neutralizers also appears to be a serious impediment (Scheid
et al., 2011; Wu et al., 2011b).
Development of Broadly Neutralizing HIV-1 Immunity
B cell ontogenies inferred from analysis of mAbs and from
next-generation sequencing provide substantial insight into the
immune processes by which unusual features of broadly
neutralizing HIV-1 antibodies are generated. These features,
uncommonly long CDR H3s or extraordinary degrees of somatic
maturation, appear to follow different paths that are specific to
the antibody specificity and its mode of recognition (Figure 2).
Whereas 20% of HIV-1-infected individuals generate broadly
neutralizing immunity, analysis of the most potent sera indicates
that serum neutralization is often conferred by only one or two
dominant antibody specificities (Binley et al., 2008; Bonsignori
et al., 2012; Tomaras et al., 2011; Walker et al., 2010). It should
be noted, however, that the humoral immune system generates
populations of B cells expressing diverse antibodies, not just
a single mAb. Even highly related antibodies can have substan-
tial differences in HIV-1 recognition—as observed explicitly
through next-generation sequencing, bioinformatics analysis,
and functional characterization of the PGT135–137-related anti-
bodies (Zhu et al., 2012). Thus, the vaunted diversity of HIV-1 is
opposed by populations of B cells expressing diverse anti-
bodies, and whereas individual mAbs can show substantial
breadths of neutralization, the polyclonal serum response is
often substantially more effective than any single antibody at
neutralizing HIV-1.
Ontogeny and Structure-Based Classification
The B cell ontogenies and structures of broadly neutralizing
HIV-1 antibodies and their recognized epitopes reviewed here
suggest a basis for classification (Table 1). In such a scheme,
structural definition of mode and of recognized site on HIV-1
Env would provide broad organization, while B cell ontogeny
would provide detail and relative placement, utilizing nomencla-
ture developed by B cell immunologists. Thus, mAbs of a
particular B cell clonal lineage would form a clonal ‘‘family,’’
and families with specified genetic similarities (e.g., related B
cell ontogenies such as VRC01-like antibodies from different
donors) would define an antibody ‘‘class.’’ Structural modes of
recognition, meanwhile, can be thought of as a ‘‘type’’ of broadly
neutralizing antibody, with the four HIV-1 sites of Env vulnera-
bility defining antibody ‘‘categories.’’ A nice feature of such an
ontogeny and structure-based classification is that family and
class can be named after the first described monoclonal
member (or if several mAbs are described at the same time,
then the most potent of the initially described antibodies).
Because the first described member of a monoclonal family is
often a touchstone for researchers in the field, this would reduce
new nomenclature and retain an association with the original
identification. Thus, for mAbs PG9 and PG16, such a naming
convention would place PG9 and PG16 in the ‘‘PG9 family,’’
because PG9 and PG16 are clonal relatives, PG9 is more effec-
tive than PG16, and both were described at the same time. If
a new family of antibodies with a B cell ontogeny similar to
PG9 were discovered, these new antibodies would form theirImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 419
Table 1. Ontogeny and Structure-Based Classification
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Reviewown family but be part of the ‘‘PG9 class’’ of antibodies. The PG9
class, meanwhile, would have ‘‘penetrating CDR H3’’ or ‘‘two
glycans and a strand’’ type of recognition and fall into the general
‘‘V1V2 site on gp120’’ category of broadly neutralizing antibodies
(Table 1). Similarly, for mAbs VRC01, 3BNC117, and 12A12,
each of these antibodies are themost potentmembers of a clonal
B cell family. These three antibodies arose in independent
donors but derive from the same genomic VH gene (VH1-2)
and share specific maturation features, and thus all three would
fall into the ‘‘VRC01 class.’’ Their ‘‘CD4 mimicry by heavy chain’’
type of recognition defines this class of antibodies within the
general ‘‘CD4-binding site on gp120’’ category. Meanwhile, the
‘‘8ANC131 class’’ of antibodies also recognizes the CD4-binding
site via heavy-chain mimicry of CD4 but derives from the VH1-46
gene rather than from VH1-2. We are cognizant that others have
described types of antibodies using properties such as binding
and neutralization, for example, highly agonistic CD4-binding
site antibodies (HAADs) described by Nussenzweig and col-
leagues (Scheid et al., 2011) and potent VRC01-like antibodies
(PVL) described by Bjorkman and colleagues (West et al.,
2012), and such naming could be used within the classification
scheme that we present. We note, however, that the classifica-420 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.tion scheme proposed here, based on structural and genetic
properties, naturally emphasizes similarities in recognition and
development, while preserving a connection to the original iden-
tification.
Discussion
The last few years have seen a renaissance in our understanding
of human antibodies that neutralize HIV-1. Much of this has been
enabled by technologies that allow for the identification of
effective neutralizers from the B cells of HIV-1-infected donors
(Scheid et al., 2009, 2011; Walker et al., 2009, 2011; Wu et al.,
2010, 2011b). Atomic-level characterization of antibody-HIV-1
Env interactions has also provided substantial insight into
the mechanism of HIV-1 neutralization (Calarese et al., 2003;
Cardoso et al., 2005; Diskin et al., 2011; McLellan et al.,
2011; Pejchal et al., 2011; Zhou et al., 2007, 2010). Next-
generation sequencing coupled to systems-level bioinformatics
holds the potential to precisely define B cell ontogenies (Wu
et al., 2011b; Zhu et al., 2012), though substantial methodolog-
ical hurdles remain, such as the current lack of pairing of heavy
and light chains produced in separate sequencing reactions or
the 1%–2% error rates of 454 pyrosequencing. Nonetheless,
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Figure 3. Broadly Neutralizing Immunity to HIV-1
Infection by HIV-1 (top panel) generates broadly neutralizing antibodies after 2 or more years of infection in 20% of individuals. Next-generation sequencing of
antibody-gene transcripts from memory B cells coupled with bioinformatics analyses of the resulting antibodyomes provides the potential to follow the devel-
opment of effective neutralizing antibodies during natural infection. HIV-1-neutralizing mAbs can potentially be used in passive modes of protection (far right
arrow connecting top and bottom panels), either singly or in combination. Based upon our understanding of the B cell ontogenies of broadly neutralizing anti-
bodies, immunogens can potentially be developed to re-create the elicitation of effective mAb neutralizers (bottom panel).
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these issues within the next few years.
Once an understanding of the B cell ontogeny of effective
HIV-1 neutralizers is achieved, it may be possible to utilize this
information in immunization strategies (Figure 3). Because these
highly effective neutralizing antibodies occur naturally, an effec-
tive vaccine against HIV-1, for example, might consist of merely
‘‘pushing the right immune system buttons’’ with immunogens.
VRC01-like antibodies might be generated by designing immu-
nogens with enhanced affinity for the VH1-2 heavy chain and 5
amino acid CDR L3-germline recombinants. The elicitation of
PG9-like antibodies might be aided by immunization in the pres-
ence of adjuvants that promote the activation of greater numbers
of naive B cells, thus potentially increasing the number of
uncommonly long CDR H3s required for this mode of HIV-1
recognition. And PGT128- and 10E8-like antibodies might
require a bit of both to enhance the elicitation of required CDRH3 length and high degree of somatic maturation. Although it
is difficult to predict how revolutions in biological understanding
might translate into improved immunological interventions, it
seems reasonable to expect that a detailed understanding of
the natural generation of effective HIV-1 neutralizers will provide
avenues toward elicitation in vaccine settings (Burton et al.,
2012; Haynes et al., 2012; Moir et al., 2011).
In addition to serving as vaccine templates, HIV-1-neutralizing
mAbs may serve other uses, for example in passive protection
against HIV-1 infection (Figure 3). As in the case of respiratory
syncytial virus infection, where the mAb palivizumab (Synagis)
is used to protect neonates from clinical disease, an effective
HIV-1 mAb or combination of antibodies (Bonsignori et al.,
2012; Doria-Rose et al., 2012b) might also serve to prevent
HIV-1 infection. Indeed, such passive antibody transfer has
already been shown to afford protection in animal models of
infection (reviewed in Mascola and Montefiori, 2010). Moreover,Immunity 37, September 21, 2012 ª2012 Elsevier Inc. 421
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vectors such as AAV show the potential for long-term expression
of protective titers of neutralizing antibodies (Balazs et al., 2012;
Johnson et al., 2009). In summary, a detailed atomic-level knowl-
edge of HIV-1 antibodies and their mechanisms of neutralization,
together with an understanding of the genetic pathways for anti-
body elicitation, is likely to lead to more effective approaches of
prophylactic protection from HIV-1. It will be exciting to see how
insight into human immunity—based on observation from natural
infection—translates into ways to ameliorate, prevent, or even
cure infection by HIV-1.
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